Anthrax is a severe infectious disease caused by bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, and loss of appetite, fever, severe bloody diarrhoea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. Global anthrax market is driven by growing threat of communicable diseases such as anthrax across the globe. Moreover cost effectiveness of immunizations, new funding opportunities from government, donors, research foundations, advances in research and manufacturing technologies expected to drive market revenue growth of anthrax vaccine over a forecast period. In addition, availability of large target population in emerging markets driving the growth of the anthrax vaccines market. However, lack of awareness, the high cost of the vaccine in under developed economies, lack of availability and affordability, stringent regulations are the factors which are restraining the growth of the anthrax vaccine market.
A sample of this report is available upon request @
Global anthrax vaccine market is segmented based on the type of vaccine, end user and geographical regions.
On the basis of type of vaccine, anthrax vaccine market is segmented as
- Live Vaccines
- Cell free PA Vaccines
On the basis of end user, anthrax vaccine market is segmented as
- Hospitals
- Clinics
- Vaccination Centers
- Others
To view TOC of this report is available upon request @
The growing efforts and the growth of the market share in the product portfolio are related to anthrax prevention. Biohield Legislation and Biohield Legislation are being developed in the United States to create and maintain sufficient vaccines against anthrax through various programs, such as the Joint Program Executive Office for Chemical and Biological Defense, Biomedical Advanced Research and Development Authority (BARDA) market players. One of the US FDA approved products against anthrax is BioThrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.
Geographically, Global anthrax vaccine is segmented into five key regions Viz. North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa. North America market expected to present better growth opportunities for market players owing to government initiatives to curb anthrax. BARDA, HHSCDC, NIAID, ASPR, and the FDA is one of the key contributing factors to the revenue generation in the North America region. Asia Pacific is expected to witness significant contributions to the R & D sector. The extensive vaccine manufacturing facilities across Japan are associated with the presence of sophisticated healthcare infrastructure in the country.
Need more information about this report @
Some of the players in the anthrax vaccine market are Emergent BioSolutions (US), Elusys Therapeutics (US), Porton Biopharma Limited (UK), and Panacea Biotec (India) to name a few.
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firms, which follows a holistic approach to solve the needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and making better decisions. We provide consulting, syndicated and customized market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX